Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Linvoseltamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Food Allergy. According to GlobalData, Phase I drugs for Food Allergy have a 78% phase transition ...

Regulatory setbacks, including the FDA’s complete response letter for linvoseltamab, further contributed to investor concerns. Analysts' consensus rating on Regeneron Pharmaceuticals stock is ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, prompting a Department of Justice enforcement action and exposing the drugmaker ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ...